About

Jessica M. Rosenberg is an Associate Professor in the Department of Literatures in English at Cornell University, based in 250 Goldwin Smith Hall. Her research and teaching focus on the literature and culture of early modern England, with additional emphasis on science and literature, the history of material texts and media forms, and the aesthetic dimensions of everyday life. She is the author of Botanical Poetics: Early Modern Plant Books and the Husbandry of Print, published by the University of Pennsylvania Press in 2023, and has contributed articles on topics such as husbandry, hospitality, poetry and plants, and the poetics of practical address. Her scholarly work explores how small epistemic forms like knacks, devices, recipes, and techniques influenced early modern comedy and everyday life. Rosenberg's writing has been published in academic journals including ELH, postmedieval, and Philological Quarterly. Currently, she is working on a book examining the role of these small epistemic forms in shaping early modern comedy and daily practices.

Research topics

• Internal medicine
• Oncology
• Medicine
• Gastroenterology
• Urology
• Surgery
• Genetics
• Pathology
• Gynecology
• Biology
• Immunology
• Cancer research

Selected publications

• Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102)

  JCO oncology advances. · 2026-04-01

  articleOpen access
  PublisherDOI

• Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research

  JCO Oncology Practice · 2025-06-16

  articleOpen access

  PURPOSE Telemedicine is increasingly used in oncology research including informed consent discussions, but data evaluating the potential impact of telemedicine on the quality of informed consent are scarce. METHODS Consecutive patients with genitourinary malignancies who underwent informed consent discussions for biomarker (next-generation sequencing) or therapeutic (phase I to III) clinical studies at the Memorial Sloan Kettering Cancer Center were asked to complete modified versions of the validated Quality of Informed Consent (QuIC) questionnaire evaluating objective (QuIC A) and subjective (QuIC B) understanding. The method used for the informed consent discussion (in-person or telemedicine) was at the physician's discretion. QuIC scores were compared between telemedicine and in-person cohorts using separate linear regression models for QuIC A and B scores and for biomarker and therapeutic protocols. Cochran's Q was calculated to evaluate heterogeneity between biomarker and therapeutic protocols. RESULTS Of 320 eligible patients approached between January 2021 and July 2022, 239 patients completed the QuIC questionnaires after informed consent discussion for biomarker (n = 128) or therapeutic (n = 111) protocols, conducted via telemedicine (n = 49) or in person (n = 190). We did not find evidence that telemedicine and in-person consent differed between the biomarker and therapeutic studies for either QuIC A or B (heterogeneity P = .13 and P = .5, Respectively), and so the main analyses combined both study types. There were no differences between groups for QuIC A (adjusted difference, –1.3 [95% CI, –4.6 to 1.9]; P = .4), but QuIC B scores were significantly higher for telemedicine versus in-person consent for the therapeutic cohort (adjusted difference, –5.2 [95% CI, –10.3 to –0.01]; P = .049). CONCLUSION Our results support the use of telemedicine for informed consent discussions in clinical cancer research studies of biomarkers and clinical trials.

  PublisherOA PDFDOI

• Abstract 89: Genomic and clinical characteristics associated with metastatic patterns in urothelial carcinoma patients

  Cancer Research · 2025-04-21

  article

  Abstract Introduction: To identify the patients with urothelial cancer (UC) at greatest risk of metastasis, we performed an integrated analysis of clinicopathologic and somatic mutation data from a prospectively generated tumor genomic sequencing cohort. Methods: We collected detailed clinicopathologic data from 1, 617 patients with bladder and upper tract UC treated at Memorial Sloan Kettering. Tumors were sequenced with MSK-IMPACT, a targeted DNA sequencing assay that identifies genomic alterations in 341-505 genes. Metastatic site involvement was inferred using a natural language processing model, as reported in the MSK-CHORD dataset. Patients were considered never metastatic if there was no evidence of metastases after 2.5 years of follow-up from diagnosis. Comparisons were made between ever-metastatic (EM) and never-metastatic (NM) patients. In a time to metastasis analysis, metastatic patients at diagnosis and patients that had metastasis within 6 months of diagnosis were excluded. Continuous variables were analyzed using Wilcoxon rank sum test and two-sided Fisher’s exact test for categorical variables. Univariable Cox proportional hazard models were used to assess time-to-metastasis. Benjamini-Hochberg was used to correct for multiple hypothesis testing and q-values <0.1 were considered significant. Results: EM patients were more likely to be former smokers (64% vs 50%, q<0.001) and be diagnosed after age 80 (17% vs 10%, q=0.033). NM patients were more likely to be never smokers (48% vs 34%, q<0.001) and diagnosed before age 65 (36% vs 28%, q=0.016). EM tumors had a higher fraction genome altered (0.20 vs 0.10, q<0.001) and higher rates of TP53 (55% vs 44%, q=0.003), ELF3 (15% vs 9%, q=0.018), and CDKN2A (29% vs 21%, q=0.069) alterations. NM tumors were more likely to have FGFR3 (18% vs 26%, q=0.002) and ERCC2 (6% vs 13%, q<0.001) alterations. In a time to metastasis analysis: former smoking (HR: 1.44, q=0.041), CDKN2A (HR: 1.59, q=0.005), and ELF3 (HR: 1.64, q=0.030) alterations were associated with a higher risk of bone metastasis. CDKN2A (HR: 1.98, q<0.001) and NRF2 pathway alterations (HR: 2.13 q=0.026) were associated with higher risk of lung metastasis. Former smoking (HR: 1.41, q=0.029), CDKN2A alterations (HR: 1.33, q=0.086), ERBB2 amplifications (HR: 1.81, q=0.009), NRF2 (HR: 1.92 q=0.026) and HIPPO (HR: 1.62 q=0.031) pathway alterations were associated with higher risk of lymph node metastasis. ERCC2 alterations were associated with lower risk of bone, (HR: 0.33, q=0.017), lung (HR: 0.48, q=0.098), and lymph node metastases (HR: 0.43, q=0.026). Conclusion: Through integration of tumor genomic profiling data with NLP-derived clinical annotation, we identified clinical and genomic features associated with a higher risk of developing metastatic disease in patients with UC, as well as alterations associated with organ-specific metastatic tropism. Citation Format: Jordan E. Eichholz, Henry Walch, Jacob Tallman, Syed Alam, James Rodrigues, Kwanghee Kim, Christopher Fong, Ecenur Turkay, Alejandra Lopez Rojas, Gopa Iyer, Eugene Pietzak, Jonathan E. Rosenberg, Hikmat Al-Ahmadie, Nikolaus Schultz, Walid K. Chatila, David B. Solit. Genomic and clinical characteristics associated with metastatic patterns in urothelial carcinoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 89.

  PublisherDOI

• End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

  Journal of Clinical Oncology · 2025-09-11 · 11 citations

  articleOpen access

  PURPOSE: The evolving treatment landscape of muscle-invasive bladder cancer (MIBC) increasingly warrants novel trial design to evaluate perioperative strategies aimed at bladder preservation. To establish standardized outcome measures for evaluating organ preservation strategies in MIBC, the International Bladder Cancer Group (IBCG) and the Global Society of Rare Genitourinary Tumors (GSRGT) assembled an international, multidisciplinary consensus panel. METHODS: The IBCG and GSRGT gathered global bladder cancer experts and patient advocates to establish a framework for risk-adapted bladder-sparing treatment approaches for MIBC. Working groups reviewed the literature and developed draft recommendations, which were discussed at a live meeting in December 2024 in Milan. This was followed by voting by the members using a modified Delphi process. Recommendations achieving ≥75% agreement during the meeting were further refined and presented. RESULTS: Clinical complete response (cCR) definition should encompass the absence of high-grade malignancy on pathology and malignant cells on urine cytology and no evidence of local or metastatic disease on cross-sectional imaging. Although cCR remains immature as a primary or coprimary end point in registrational trials, it could serve as a suitable end point in early-phase studies and risk-adapted investigations. Event-free survival (EFS) remains the preferred primary end point as it could reliably capture the durability of clinically meaningful benefit after omittance of surgical consolidation or chemoradiation. Given the composite nature of EFS, events should be prespecified, evaluated in an intention-to-treat approach, and meticulously collected. Continuous assessment of individual patient preferences should begin at the outset of perioperative therapy discussions, with informed decision making prioritized throughout. CONCLUSION: The consensus definition of cCR and the framework presented in this study can serve as a foundation for thorough testing of risk-adapted bladder-sparing treatment paradigms for MIBC.

  PublisherOA PDFDOI

• PD37-03 CLINICAL UTILITY OF GENOMIC SEQUENCING IN PATIENTS WITH LOCALIZED BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY

  The Journal of Urology · 2025-04-08

  article
  PublisherDOI

• Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601

  JCO Precision Oncology · 2025-07-01 · 2 citations

  articleOpen accessSenior author

  PURPOSE In urothelial carcinoma, prior studies have indicated that the basal/squamous molecular subtype and the presence of select DNA damage response (DDR) gene alterations are associated with improved benefit from cisplatin-based chemotherapy. We sought to evaluate these biomarkers in specimens from the phase III Cancer and Leukemia Group B (CALGB) 90601 trial. METHODS We performed whole-transcriptome sequencing (n = 188) and exon capture DNA sequencing (n = 208) on pretreatment tumors from the CALGB 90601 randomized trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with treatment-naïve metastatic bladder cancer. Whole-exome sequencing (WES) was performed on tumors from 22 patients who exhibited rapid progression or durable response. Tumors were assigned to molecular subtypes using three different classifiers. Proportional hazards model was used to correlate molecular subtype with overall survival (OS) and progression-free survival (PFS), adjusting for stratification factors and treatment arm (for PFS). RESULTS Patients with basal tumors had the shortest PFS and OS in the entire cohort. PFS was numerically longer in patients with basal tumors receiving bevacizumab. DDR gene alterations were not associated with improved outcomes. FRY , a candidate predictive biomarker of chemosensitivity identified by WES, did not confer sensitivity to cisplatin or gemcitabine in functional studies. CONCLUSION Molecular subtype and DDR alterations did not correlate with improved outcomes in CALGB 90601. Possible explanations for these results include the small cohort size, lack of strong therapeutic effects of the treatments, genomic heterogeneity between profiled specimens and the metastatic lesions under treatment pressure, and differences in biology associated with different disease states (muscle-invasive v metastatic disease).

  PublisherOA PDFDOI

• Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists

  Clinical Genitourinary Cancer · 2025-12-20

  articleOpen access

  BACKGROUND: Immune checkpoint inhibitors (ICI) are commonly used in urothelial carcinoma. We sought to understand provider preferences for subsequent treatment of patients after prior ICI. MATERIALS AND METHODS: We comprised a group of 11 expert genitourinary medical oncologists in the United States and created a survey regarding treatment sequencing. We present the final responses to this survey, using descriptive statistics. RESULTS: We received 78 responses (34%) from 227 genitourinary oncologists between May and August 2024; most were practicing for >5 years (62%) and were seeing >25 patients with metastatic urothelial carcinoma (mUC) yearly (72%). For patients with progression while receiving adjuvant ICI, 51% of respondents were somewhat/very likely to use enfortumab vedotin/pembrolizumab (EVP) as next therapy line. For patients with progression after prior ICI, 1/3 of respondents would consider first-line (1L) EVP irrespective of the interval from prior ICI completion. For ICI given in nonmuscle invasive bladder cancer and muscle-invasive bladder cancer, 43% and 45%, respectively would consider EVP > 6 months post-ICI completion. After progression on EVP, 77% were somewhat/very likely to give platinum-based chemotherapy, and most would not include combination or switch maintenance ICI. Similarly, 80% were somewhat/very likely to recommend non-ICI clinical trials in the second-line setting after EVP, and 87% were somewhat/very likely to offer erdafitinib for susceptible FGFR3 alterations. CONCLUSION: Survey-based opinions can effectively capture treatment selection preferences for mUC and could inform future clinical trial design. Additional data, including the impact of residual toxicity from 1L EVP, are needed to better understand real-world treatment sequencing patterns.

  PublisherOA PDFDOI

• Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma.

  Journal of Clinical Oncology · 2025-05-28 · 5 citations

  articleSenior author

  4573 Background: Enfortumab vedotin and pembrolizumab (EV/P) emerged as the new standard of care for previously untreated metastatic urothelial carcinoma (mUC), shifting the treatment paradigm. Currently, there are no guidelines for management after EV/P as the outcomes of subsequent systemic treatments, including platinum-based chemotherapy, remain unknown. Methods: Our retrospective cohort of patients with mUC treated with EV/P at Memorial Sloan Kettering Cancer Center was reviewed to identify patients receiving subsequent systemic treatments. Clinical data were collected by chart review. Response to EV/P and platinum-based chemotherapy was determined by physician assessment using RECIST v1.1. Progression free and overall survival (PFS, OS) were calculated using the Kaplan-Meier method. Results: Of 208 patients treated with EV/P between 10/2018 and 9/2024, we identified 56 patients that received any subsequent systemic treatments. In 68% of patients (n = 38), the initial post EV/P regimen administered was platinum-based chemotherapy. Other therapies included sacituzumab govitecan (n = 6), clinical trials (n = 5), trastuzumab deruxtecan (n = 4), erdafitinib (n = 2) and non-platinum chemotherapy (n = 1). In the 38 patients treated with platinum-based chemotherapy, median age was 74 years, 66% were men, 32% had upper tract primary and divergent histology/subtype component was reported in 47% of cases. One patient had prior platinum exposure (neoadjuvant treatment with rapid metastatic recurrence < 6 months). 16 patients had disease response to EV/P (observed response rate [ORR] 42%, 95% CI 27%, 59%). 36 patients (95%) received doublet therapy with gemcitabine and either cisplatin (n = 7) or carboplatin (n = 29), the two remaining patients received carboplatin/gemcitabine/paclitaxel and carboplatin/etoposide. 7 patients (18%) received maintenance avelumab following platinum. Median follow up was 5 months (IQR: 2.5-6.3). ORR was 50% (95% CI 34%, 66%), including one patient with complete response (CR; 2.9%) and 16 patients with partial response (PR; 47%). Among the patients with CR or PR, median duration of response was 3.8 months (IQR: 2.0-4.6). Median PFS was 4.4 months (95% CI 3.7, 7.8) and median OS was 12 months (95% CI 9.7, 17). Conclusions: In a real-world cohort of patients with mUC, platinum-based chemotherapy had substantial antitumor activity after EV/P, although progression-free survival and duration of response were modest. This work provides useful information to further future trial design in the post EV/P setting. Disease response with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab. N=38 (%) 95% CI Observed response rate 17 (50%) 34%, 66% Complete response 1 (2.9%) 0.15%, 17% Partial response 16 (47%) 30%, 65% Stable disease 6 (18%) 7.4%, 35% Progressive disease 11 (32%) 18%, 15% Unknown 4

  PublisherDOI

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  CA A Cancer Journal for Clinicians · 2025-12-13

  articleOpen access

  The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence-based expert consensus recommendations for optimal management. A multidisciplinary panel of 51 experts participated in a modified Delphi process addressing questions developed through iterative consensus-building covering RCC and UTC management. Voting occurred before and after the conference, and analyses focused on postmeeting responses. Consensus was defined as ≥75% agreement, with strong consensus as >90%. Strong consensus was found on the use of adjuvant pembrolizumab for higher risk RCC (pathologic T2 [pT2], grade 4; pT3-pT4, any grade; pTXN1; or fully resected metastatic disease) and on neoadjuvant therapy before cystectomy for localized UTC. There was strong consensus on the use of enfortumab vedotin plus pembrolizumab as frontline therapy for metastatic UTC and the use of platinum-based chemotherapy postprogression in biomarker-negative UTC. For RCC, there was consensus on the role of single-agent vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy after progression on frontline immune checkpoint inhibitor/vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy or dual immune checkpoint inhibitor therapy. However, there was a lack of consensus on other critical areas in the management of RCC and UTC. The 2025 Advanced Urologic Cancer Consensus Conference provides evidence-informed guidance for complex clinical scenarios while identifying critical research priorities. The group recognizes that the lack of consensus across multiple areas highlights the need for improved patient selection and prospective studies enabling optimal combination and sequencing approaches. This iterative annual process will address evolving treatment paradigms to optimize outcomes.

  PublisherOA PDFDOI

• 920 Correlation of NECTIN4 Amplification and Expression with Response to Enfortumab Vedotin (EV) Treatment in Locally Advanced or Metastatic Urothelial Carcinoma

  Laboratory Investigation · 2025-03-01

  articleOpen access
  PublisherOA PDFDOI

Recent grants

• SPORE in Bladder Cancer

  NIH · $23.9M · 2018–2025

• NIH Grant R21CA164613

  NIH · $454k · 2015

Frequent coauthors

• Toni K. Choueiri

  Dana-Farber Cancer Institute

  583 shared

• Dean F. Bajorin

  Memorial Sloan Kettering Cancer Center

  492 shared

• Joaquim Bellmunt

  Dana-Farber Cancer Institute

  421 shared

• Hikmat Al‐Ahmadie

  Memorial Sloan Kettering Cancer Center

  408 shared

• Bernard H. Bochner

  307 shared

• Gopa Iyer

  Memorial Sloan Kettering Cancer Center

  302 shared

• David B. Solit

  291 shared

• Philip W. Kantoff

  260 shared

Education

• MD

  Harvard Medical School

  1997